Regenerative Medical Technology RMTG
OTC RMTG
$0.06 +0.00 (+0.00%)
At close: Oct 2, 2026 · 4:00 PM EDT

Regenerative Medical Technology (RMTG) Liabilities from Discontinued Operations (2022)

Updated

Regenerative Medical Technology (RMTG) recorded Liabilities from Discontinued Operations of $68,313 in Q4 2022.

Analysis

Regenerative Medical Technology (RMTG) Liabilities from Discontinued Operations (2022) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn
10 Regenerative Medical Technology 824,338.06 -3.70 Mn 2.58 Mn
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2022 68,313.00
API Access

Regenerative Medical Technology Liabilities from Discontinued Operations API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=liabilities-from-discontinued-operations&ticker=RMTG&period=max&api_key=YOUR_API_KEY